Compounds > pioglitazone
Page last updated: 2024-11-02

pioglitazone and Acute Coronary Syndrome

pioglitazone has been researched along with Acute Coronary Syndrome in 7 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial."9.30Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019)
"Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event."9.24Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, AM; Pfau, SE; Schwartz, GG; Viscoli, CM; Young, LH, 2017)
"This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)."9.14Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009)
"To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial."5.30Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019)
"Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event."5.24Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, AM; Pfau, SE; Schwartz, GG; Viscoli, CM; Young, LH, 2017)
"This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)."5.14Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009)
"Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone."3.77Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spence, JD1
Viscoli, CM2
Inzucchi, SE2
Dearborn-Tomazos, J1
Ford, GA1
Gorman, M1
Furie, KL2
Lovejoy, AM2
Young, LH2
Kernan, WN2
Christoph, M1
Herold, J1
Berg-Holldack, A1
Rauwolf, T1
Ziemssen, T1
Schmeisser, A1
Weinert, S1
Ebner, B1
Said, S1
Strasser, RH1
Braun-Dullaeus, RC1
Curtis, JP1
Schwartz, GG1
Gorman, MJ1
Conwit, R1
Abbott, JD1
Jacoby, DL1
Kolansky, DM1
Pfau, SE1
Ling, FS1
Hirano, M1
Nakamura, T1
Kitta, Y1
Yano, T1
Kobayashi, T1
Sano, K1
Fujioka, D1
Saito, Y1
Kodama, Y1
Kawabata, K1
Nakamura, K1
Obata, JE1
Kugiyama, K1
Gallagher, AM1
Smeeth, L1
Seabroke, S1
Leufkens, HG1
van Staa, TP1
Chibana, H1
Mitsutake, Y1
Itaya, N1
Ueno, T1
Komiyama, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949]Phase 33,876 participants (Actual)Interventional2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acute Coronary Syndrome

Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone206
Placebo249

All Cause Mortality

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone136
Placebo146

Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone206
Placebo249

Decline in Cognitive Status

Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)

Interventionunits on a scale (Mean)
Pioglitazone0.27
Placebo0.29

Development of Overt Diabetes

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone73
Placebo149

Fatal or Non-fatal Stroke Alone

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone127
Placebo154

Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction

(NCT00091949)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Pioglitazone175
Placebo228

Reviews

2 reviews available for pioglitazone and Acute Coronary Syndrome

ArticleYear
[Stabilization of vulnerable coronary plaque].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Acute Coronary Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pioglitazone; Plaqu

2011
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu

2011

Trials

5 trials available for pioglitazone and Acute Coronary Syndrome

ArticleYear
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
    JAMA neurology, 2019, 05-01, Volume: 76, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemo

2019
Effects of the PPARĪ³ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.
    Heart and vessels, 2015, Volume: 30, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Dis

2015
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
    Circulation, 2017, May-16, Volume: 135, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Femal

2017
Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome.
    Atherosclerosis, 2009, Volume: 203, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Calibration; Carotid Stenosis; Diabetes Complications; Diabetes Melli

2009
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu

2011

Other Studies

1 other study available for pioglitazone and Acute Coronary Syndrome

ArticleYear
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases

2011